Skip to main content
. 2013 Apr 20;16(4):203–210. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2013.04.06

5.

66例患者治疗平均成本对比分析(包括每个周期的靶向治疗药物费用, 治疗药物不良反应的药物以及相应住院费用)

The average cost analysis of 66 patients (including the cost of drugs, the treatment of adverse effects, and cost of hospitalization)

Outcome/1 cycle Gefitinib (RMB) Erlotinib (RMB)
Guangzhou medical insurance fixed payment procedure was started from February 2010, the patients who enrolled before were excluded from the analysis of cost-effectiveness with medical insurance.
* Guangzhou medical insurance can cover 15, 000 RMB at most for patients per month.
Cost of drugs 16, 351 19, 731
Cost of laboratory and imaging test 1, 288 1, 352
Cost of adverse event
 Rash 77 236
 Diarrhea 11 39
 Liver damage 35 15
Cost of hospitalization 265 427
Hypothetical PFS (months) 17.5 13.0
Without medical insurance
Total costs 315, 472 283, 400
Cost-effectiveness ratio 18, 027 21, 800
ICER per PF-LYS Referent 1.21
With medical insurance*
Medical insurance * -262, 500 -195, 000
Total costs 52, 972 88, 400
Cost-effectiveness ratio 3, 027 6, 800
ICER per PF-LYS Referent 2.25